Merck (MRK) reported third-quarter results that beat Wall Street expectations and raised its full-year 2026 profit outlook, fueled by stronger sales of cancer blockbuster Keytruda and newer medicines.
The New Jersey-based drugmaker reported non-GAAP earnings of $2.49 per share, beating To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser